The first drug targeting the cause of Huntington’s disease was safe and well-tolerated in its first human trial led by UCL scientists. It successfully lowered the level of the harmful huntingtin protein in the nervous system.
After over a decade in pre-clinical development, this first human trial of huntingtin-lowering drug began in late 2015, led by Professor Sarah Tabrizi (UCL Institute of Neurology) and sponsored by Ionis Pharmaceuticals.
The trial involved enrolling 46 patients with early Huntington’s disease at nine study centres in the UK, Germany and Canada.
Each patient received four doses of either IONIS-HTTRx or placebo, given by injection into the spinal fluid to enable it to reach the brain. As the phase 1/2a trial progressed, the dose of IONIS-HTTRx was increased several times according to the ascending-dose trial design.
Patient safety was monitored throughout the study by an independent safety committee.
Today’s announcement at completion of the trial confirms that IONIS-HTTRx was well-tolerated by the trial participants and its safety profile supports further testing in patients.
Professor Tabrizi, Director of the UCL Huntington’s Disease Centre and IONIS-HTTRx Global Chief Investigator, said: “The results of this trial are of ground-breaking importance for Huntington’s disease patients and families. For the first time a drug has lowered the level of the toxic disease-causing protein in the nervous system, and the drug was safe and well-tolerated. The key now is to move quickly to a larger trial to test whether the drug slows disease progression.”
A major unknown was whether the trial would show that IONIS-HTTRx could lower the level of mutant huntingtin protein in the nervous system. Using an ultra-sensitive assay, concentrations of the protein were measured in each patient’s spinal fluid before and after treatment.
As hoped, IONIS-HTTRx produced significant, dose-dependent lowering of the level of mutant huntingtin – the first time the protein known to cause Huntington’s has been lowered in the nervous system of patients.
As a result of these successful outcomes, Ionis’ partner, Roche, has exercised its option to license IONIS-HTTRx and assumes responsibility for further development, regulatory activities and commercialization activities. Meanwhile, Ionis announced in June that all patients in the completed trial would be offered a place in an open-label extension to receive IONIS-HTTRx.
Learn more: Drug lowers deadly Huntington’s disease protein
The Latest on: Huntington’s disease
- Experimental Treatment for Rare Children's Disease to be Discontinuedon March 5, 2021 at 12:38 pm
Niemann-Pick is a disease and Adrabetadex is an experimental treatment you likely might not have heard of, but what can be familiar to many parents, is the desire to do anything to keep their children ...
- Huntington's disease driven by slowed protein-building machinery in cellson March 5, 2021 at 10:04 am
In 1993, scientists discovered that a single mutated gene, HTT, caused Huntington's disease, raising high hopes for a quick cure. Yet today, there's still no approved treatment.
- Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington diseaseon March 5, 2021 at 4:57 am
Huntington disease (HD) is a neurodegenerative disorder caused by the expansion of a polyglutamine tract in the huntingtin (mHtt) protein. Here the authors suggest that mHtt promotes ribosome stalling ...
- Emsworth 15-year-old set for charity skydive to raise funds and awareness for Huntington's Diseaseon March 5, 2021 at 3:41 am
A 15-year-old fundraising champion is preparing to skydive from 15,000ft to raise money for a cause close to her heart.
- Our ancient ancestor Little Foot was 'relatively old' when she died 3.67 million years ago and survived disease or malnutrition as a child, new X-ray analysis of her skull revealson March 4, 2021 at 7:27 am
Discovered in South Africa in the mid-90s Little Foot's fossil was analysed in Oxfordshire with super high resolution X-ray images.
- Get into the swing: Golf is better than tai chi for improving balance and mobility in people with Parkinson's diseaseon March 3, 2021 at 1:00 pm
Volunteers with Parkinson's in the US were asked to either practice their golf swing or take Tai Chi lessons for ten weeks and have their mobility tested before and after the session.
- Basic cell health systems wear down in Huntington’s disease, analysis showson February 24, 2021 at 10:43 am
A new method of computational analysis of vast gene expression datasets has produced new insights into Huntington's disease, for instance by pinpointing processes needed to maintain cellular health ...
- Study identifies potential therapeutic target for treatment of Huntington's diseaseon February 23, 2021 at 2:20 pm
Huntington's disease is caused by a mutation in the Huntingtin gene (HTT), which appears in adults and features motor, cognitive and psychiatric alterations.
- Basic cell health systems wear down in Huntington's disease, novel analysis showson February 23, 2021 at 1:46 am
Using an innovative computational approach to analyze vast brain cell gene expression datasets, researchers at MIT and Sorbonne Université have found that Huntington's disease may progress to advanced ...
- Allie LaForce and Joe Smith share emotional IVF journey as they work to help others fight against Huntington’s diseaseon February 22, 2021 at 4:33 pm
A local couple is sharing their own family’s journey with Huntington’s disease in hopes of helping others battling the illness. Former FOX 8 personality and ...
via Google News and Bing News